Investing.com -- Outlook Therapeutics (NASDAQ:OTLK) stock plummeted 67.7% in after-hours trading Wednesday after the company announced that U.S. regulators rejected its application for a bevacizumab ...

Outlook Therapeutics received notice that the Food and Drug Administration can't approve its biologics license application for a drug designed to treat macular degeneration. The Iselin, N.J., ...

The rejected application was based on data from the NORSE clinical trial program, including the pivotal NORSE TWO trial and the NORSE EIGHT study, which evaluated ONS-5010 versus ranibizumab. Outlook ...

Mapi León and Ingrid Engen are more than exceptional football players; they are the embodiment of what women’s football looks like in today’s era: skilled, considerate, and refreshingly real. As key ...

Fundamental research into the mechanisms behind cancers at an institution in Japan is leading to new approaches for tackling these notoriously complex diseases. Every year, up to 20 million people in ...